CV Events: Safety of Insulin

Video

A study compared mortality and major adverse cardiovascular events in patients with type 2 diabetes prescribed metformin or insulin.

A retrospective cohort study published in The Lancet Diabetes and Endocrinology sought to look at the association between insulin dose and mortality and major adverse cardiovascular events in patients with T2DM.

The study was drawn from primary care records from the UK-based Clinical Practice Research Datalink that identified new users of metformin and those who had a new prescription for insulin.

According to the authors, the take-home message is, “The result from the study reassures both patients and physicians of the overall safety and absence of major cardiovascular harms of insulin in the treatment of type 2 diabetes.”

 

Related Videos
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Should We Reclassify Diabetes Subtypes?
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
Video 8 - "Pathophysiology of Hypercortisolism"
Video 7 - "Evolving Perception of Autonomous Adrenal Hypercortisolism "
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
© 2024 MJH Life Sciences

All rights reserved.